非酒精性脂肪性肝病中的粪便真菌组
研究对78例非酒精性脂肪性肝病(NAFLD)患者、16例对照和73例酒精使用障碍患者进行粪便真菌ITS2测序,并检测抗白色念珠菌IgG。非肥胖NAFLD合并更晚期疾病者粪便真菌组组成不同,抗真菌治疗可改善小鼠饮食诱导的脂肪性肝炎。
要点
- 非肥胖NAFLD合并NASH或F2-F4纤维化者粪便真菌组特征不同,毛霉属/酿酒酵母菌log比值升高。
- 非肥胖NASH患者白色念珠菌/酿酒酵母菌log比值显著高于非肥胖NAFL患者或对照。
- 定植人类NASH粪便的无菌小鼠接受两性霉素B后免受西方饮食诱导的脂肪性肝炎。
核心结论
- 非肥胖NAFLD且疾病更晚期者粪便真菌组组成与轻度疾病者不同,抗真菌治疗可改善小鼠饮食诱导的脂肪性肝炎,肠道真菌可能是减轻NASH的靶点。
研究设计与样本
- 对78例NAFLD患者、16例对照和73例酒精使用障碍患者的粪便样本进行真菌内转录间隔区2测序。
- 检测17例对照和79例NAFLD患者血样本中的抗白色念珠菌IgG。
- 使用Songbird多名义回归工具研究真菌组变化。
- 无菌小鼠定植NASH患者粪便后接受西方饮食20周并给予抗真菌药两性霉素B治疗。
主要发现
- 非肥胖NASH或F2-F4纤维化与特定粪便真菌组特征相关,NASH和F2-F4纤维化患者毛霉属/酿酒酵母菌log比值升高。
- 非肥胖NASH患者白色念珠菌/酿酒酵母菌log比值显著高于非肥胖NAFL患者或对照。
- NAFLD合并晚期纤维化患者与酒精使用障碍合并晚期纤维化患者的粪便真菌组组成不同。
- NAFLD合并晚期纤维化患者血浆抗白色念珠菌IgG升高。
- 定植人类NASH粪便并接受两性霉素B治疗的无菌小鼠免受西方饮食诱导的脂肪性肝炎。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Studies investigating the gut-liver axis have largely focused on bacteria, whereas little is known about commensal fungi. We characterized fecal fungi in patients with non-alcoholic fatty liver disease (NAFLD) and investigated their role in a fecal microbiome-humanized mouse model of Western diet-induced steatohepatitis. METHODS: We performed fungal internal transcribed spacer 2 sequencing using fecal samples from 78 patients with NAFLD, 16 controls and 73 patients with alcohol use disorder. Anti-Candida albicans (C. albicans) IgG was measured in blood samples from 17 controls and 79 patients with NAFLD. Songbird, a novel multinominal regression tool, was used to investigate mycobiome changes. Germ-free mice were colonized with feces from patients with non-alcoholic steatohepatitis (NASH), fed a Western diet for 20 weeks and treated with the antifungal amphotericin B. RESULTS: The presence of non-obese NASH or F2-F4 fibrosis was associated with a distinct fecal mycobiome signature. Changes were characterized by an increased log-ratio for Mucor sp./Saccharomyces cerevisiae (S. cerevisiae) in patients with NASH and F2-F4 fibrosis. The C. albicans/S. cerevisiae log-ratio was significantly higher in non-obese patients with NASH when compared with non-obese patients with NAFL or controls. We observed a different fecal mycobiome composition in patients with NAFLD and advanced fibrosis compared to those with alcohol use disorder and advanced fibrosis. Plasma anti-C. albicans IgG was increased in patients with NAFLD and advanced fibrosis. Gnotobiotic mice, colonized with human NASH feces and treated with amphotericin B were protected from Western diet-induced steatohepatitis. CONCLUSIONS: Non-obese patients with NAFLD and more advanced disease have a different fecal mycobiome composition to those with mild disease. Antifungal treatment ameliorates diet-induced steatohepatitis in mice. Intestinal fungi could be an attractive target to attenuate NASH. LAY SUMMARY: Non-alcoholic fatty liver disease is one of the most common chronic liver diseases and is associated with changes in the fecal bacterial microbiome. We show that patients with non-alcoholic fatty liver disease and more severe disease stages have a specific composition of fecal fungi and an increased systemic immune response to Candida albicans. In a fecal microbiome-humanized mouse model of Western diet-induced steatohepatitis, we show that treatment with antifungals reduces liver damage.
引用
- Demir M, Lang S, Hartmann P, et al. The fecal mycobiome in non-alcoholic fatty liver disease. J Hepatol. 2021. PMID: 34896404. doi:10.1016/j.jhep.2021.11.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。